J&J seeks expanded approvals for paediatric HIV-1 therapy
Johnson & Johnson has sought approval from the US FDA for the use of its HIV-1 therapy, PREZCOBIX, in children aged six years and above.
Johnson & Johnson has sought approval from the US FDA for the use of its HIV-1 therapy, PREZCOBIX, in children aged six years and above.
What's Your Reaction?
